Park Hae Jin, Kim Hak Jae, Wu Hong-Gyun, Kim Hans, Ha Sung Whan, Kang Soon-Beom, Song Yong-Sang, Park Noh-Hyun, Kim Jae-Won
Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Korea.
Radiat Oncol J. 2011 Dec;29(4):228-35. doi: 10.3857/roj.2011.29.4.228. Epub 2011 Dec 28.
To evaluate the impact of postoperative radiotherapy (PORT) on patterns of failure and survivals in uterine carcinosarcoma patients treated with radical surgery.
Between October 1998 and August 2010, 19 patients with stage I-III uterine carcinosarcoma received curative hysterectomy and bilateral salpingo-oophorectomy with or without PORT at Seoul National University Hospital. Their hospital medical records were retrospectively reviewed. PORT and non-PORT groups included 11 and 8 patients, respectively. They were followed for a mean of 22.7 months (range, 7.8 to 126.6 months).
At 5 years, the overall survival rates were 51.9% for entire, 61.4% for PORT, and 41.7% for non-PORT groups, respectively. There was no statistical difference between PORT and non-PORT groups with regard to overall survival (p = 0.682). Seven out of 19 (36.8%) patients showed treatment failures, which all happened within 12 months. Although the predominant failures were distant metastasis in PORT group and loco-regional recurrence in non-PORT group, there was no statistically significant difference in loco-regional recurrence-free survival (LRRFS) (p = 0.362) or distant metastasis-free survival (DMFS) (p = 0.548). Lymph node metastasis was found to be a significant prognostic factor in predicting poor LRRFS (p = 0.013) and DMFS (p = 0.021), while the International Federation Gynecology and Obstetrics (FIGO) stage (p = 0.043) was associated with LRRFS.
Considering that adjuvant radiotherapy after surgical resection was effective to decrease loco-regional recurrence and most treatment failures were distant metastasis, multimodal therapy including surgery, radiotherapy, and chemotherapy might be an optimal treatment for uterine carcinosarcoma patients.
评估术后放疗(PORT)对接受根治性手术治疗的子宫癌肉瘤患者的失败模式和生存率的影响。
1998年10月至2010年8月期间,19例I - III期子宫癌肉瘤患者在首尔国立大学医院接受了根治性子宫切除术及双侧输卵管卵巢切除术,部分患者接受了PORT。对他们的医院病历进行回顾性分析。PORT组和非PORT组分别有11例和8例患者。平均随访22.7个月(范围7.8至126.6个月)。
5年时,总体生存率分别为:全部患者51.9%,PORT组61.4%,非PORT组41.7%。PORT组和非PORT组在总生存率方面无统计学差异(p = 0.682)。19例患者中有7例(36.8%)出现治疗失败,均发生在12个月内。虽然PORT组主要失败为远处转移,非PORT组主要为局部区域复发,但局部区域无复发生存率(LRRFS)(p = 0.362)或远处转移无复发生存率(DMFS)(p = 0.548)无统计学显著差异。发现淋巴结转移是预测LRRFS不良(p = 0.013)和DMFS不良(p = 0.021)的重要预后因素,而国际妇产科联盟(FIGO)分期(p = 0.043)与LRRFS相关。
鉴于手术切除后辅助放疗可有效降低局部区域复发,且大多数治疗失败为远处转移,包括手术、放疗和化疗的多模式治疗可能是子宫癌肉瘤患者的最佳治疗方法。